기본 정보
- CAS
139145-84-9- 표준 SMILES
Cl.O=c1[nH]nc(OCCCc2ccc(Cl)cc2)c(NCc2cccnc2)c1Br- InChIKey
QWGUGDYWUADMGB-UHFFFAOYSA-N- 분자식
- C19H19BrCl2N4O2
- 평균 분자량
- 486.2 g/mol
- 단동위원소 질량
- 484.00684
개요
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma. In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. Intermittent claudication is a major symptom of arteriosclerosis obliterans. It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment. Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited
이름 및 식별자
- 우선 이름
- NM-702
- IUPAC
- 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochloride
이름 및 동의어
NM-702RefChem:858687Parogrelil hydrochloride878796-94-265O9DMS368UNII-65O9DMS368139145-84-93(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1)5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochlorideNM702Parogrelil (hydrochloride)orb1699721
이름 더 보기
SCHEMBL1739368QWGUGDYWUADMGB-UHFFFAOYSA-NDTXSID701007830AKOS0407491174-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochlorideCS-0034672T282964-Bromo-6-[3-(4-chlorophenyl)propoxy]-5-{[(pyridin-3-yl)methyl]amino}pyridazin-3-ol--hydrogen chloride (1/1)
데이터베이스 식별자
- CAS
139145-84-9、878796-94-2- PubChem CID
- 9848253
- DTXSID
DTXSID701007830- UNII
- 65O9DMS368
물성
구조 계산 물성
- 극성 표면적
- 75.6 Ų
- 수소 결합 공여자 수
- 3
- 수소 결합 수용자 수
- 5
- 회전 가능 결합 수
- 8
- 무거운 원자 수
- 28
- 형식 전하
- 0
- 복잡도
- 576
화학 및 산업
약리 정보
Pharmacodynamics
Intermittent claudication is a major symptom of arteriosclerosis obliterans. It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited. NM-702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase.
Mechanism of ActionNM-702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase.
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…